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Pain perception in young infants and newborns did not receive much attention until recently. There have been valid concerns regarding the safety of administering potent 
opiates and sedatives to children due to the potential risk of airway 
compromise and respiratory depression. Inadequate sedation and 
analgesia for painful procedures in children are also aided by 
the fact that the adult health-care providers can often physically 
overpower children.
The increasing number of procedures being performed in 
children has led to a phenomenal demand for safe, predictable, 
efficacious, and cost-effective sedation in varied settings. A non-
invasive route of drug administration may be useful to obtain 
short-term sedation for procedures in uncooperative children. 
Intranasal delivery offers unique advantages that may allow 
more efficient use of resources, more rapid patient care, and 
higher patient, and provider satisfaction. Delivery of intranasal 
medication is also relatively painless, inexpensive, and easy to 
administer with a minimum of training [1].
Midazolam is the most commonly used benzodiazepine as it 
possesses many properties desirable for use in children such as 
short half-life, faster onset of action, wide toxic and therapeutic 
ratio, safety margin, and dose-dependent anxiolytic action. 
Previous studies have shown that therapeutic levels of midazolam 
in the cerebrospinal fluid indicate a more rapid rate of absorption 
through intranasal administration compared to the oral route, 
due to the rich vascular plexus cavity that communicates with 
the subarachnoid space through the olfactory nerve [2]. Intranasal 
midazolam has been used successfully in a variety of pediatric 
clinical situations, such as laceration repair, dental extractions, 
ophthalmological tests, burns patients, and venepuncture. The 
onset of action of intranasal midazolam is within 10–20 min of 
administration and the duration of its effect lasts for 30–60 min [3].
Most of the previous studies have used the undiluted 
parenteral formulation containing 5 mg/ml midazolam through 
intranasal route with a syringe by drop instillation; this reduces 
its bioavailability and increases the discomfort. A mucosal 
atomizer device delivers the medication through a fine spray 
over a broad surface area in the nasal cavity. By this technique, 
the absorption of midazolam through the nasal mucosa has been 
reported to be virtually complete (83%), because very little 
of the drug is swallowed unlike through the drop instillation 
technique [4]. Midazolam given intranasally has been shown to 
be safe, easy to administer, and effective in children undergoing 
various procedures. There were hardly any studies comparing the 
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effectiveness of intranasal midazolam versus intravenous (IV) 
midazolam for procedural sedation in children; hence, an attempt 
was made to study the efficacy and safety profile of intranasal 
midazolam as a procedural sedative.
MATERIALS AND METHODS
This was a prospective open-label randomized controlled study 
conducted in the Department of Pediatrics, Kerala Institute of 
Medical Sciences, Trivandrum, during the period between June 
2012 and May 2014. The study was approved by the Hospital 
Ethical Committee. As literature review did not show any similar 
previous studies, a pilot study was conducted on 50 children, 
based on which the sample size was calculated. A sample size 
of 123 children each in the groups receiving intranasal and IV 
midazolam was calculated [5].
All children between the ages of 6 months and 12 years, who 
underwent any invasive (lumbar puncture, central line insertion, 
suture removal, burns wound care, wound dressing changes, 
liver biopsy, skin biopsy, IV cannulation in apprehensive 
children, intercostal drainage, or esophagogastroduodenoscopy,) 
or non-invasive procedures (magnetic resonance imaging 
[MRI], computed tomography [CT], echocardiography, and 
ultrasonography) in our hospital were included in the study. 
Children with allergy to benzodiazepines or any of its components, 
hemodynamically or neurologically unstable children and 
critically ill children were excluded from the study.
A computer-generated block randomization table was created 
by personnel with no clinical involvement in the trial. This 
allocation list was held by the pediatric intensive care unit (PICU) 
in-charge nurse. Children fulfilling the inclusion criteria were 
formally enrolled in the study after informed parental consent. 
After enrolment, the PICU in-charge nurse was contacted to assign 
allocation to each new participant, based on the allocation list.
A predation evaluation was carried out. One group received 
0.3 mg/kg of intranasal midazolam with mucosal atomizer device 
(Insed atomizer, 5 mg/ml, 0.5 mg/puff, Samarth pharma) while 
the second group received 0.15 mg/kg of IV midazolam for 
sedation. A lidocaine-prilocaine (prilox) patch was applied for 
topical analgesia 45 min before procedure for all children in both 
groups undergoing invasive procedures. Prilox was also applied 
before securing IV access in children who did not previously have 
an IV line so that the confounding effect of needlestick could be 
avoided. Sedation was administered to all children by a pediatric 
resident under the supervision of a pediatric intensivist. Routine 
behavior management techniques such as tender loving care and 
minimal physical restraint were required to manage children of 
both groups during various procedures. As per hospital protocol, 
parents were not allowed to be with the children during any 
invasive procedures.
Baseline demographic variables and vitals were noted. Vitals 
were then continuously monitored and recorded in a structured 
data collection sheet every 30 min till recovery from sedation. 
Sedation score was rated only once, after administering the drug, 
just before performing the procedure, using the University of 
Michigan Sedation Score (0 - awake, alert; 1 - minimally sedated, 
responds to verbal conversation; 2 - moderately sedated, responds 
to tactile stimulation; 3 - deeply sedated; responds to significant 
physical stimulation; and 4 - unarousable) in both the groups [6]. 
Procedure was done 15 min after intranasal and 5 min after IV 
administration of midazolam.
The ease of performance was scored during the procedure 
(1 - violent movements; 2 - continuous movements; 3 - controllable 
movements; and 4 - no movements, no crying) [7]. The number 
of successfully completed procedures was noted. The child was 
monitored until he/she was able to walk (if age appropriate) and 
gave age-appropriate responses to verbal commands, but the time 
to recovery was not recorded [8]. If the sedation was not adequate 
in either group of children, the child was reverted to standard 
PICU sedation protocol and was taken as a case of “sedation 
failure.” Adverse events were noted and defined as follows:
•	 Hypoxemia:	SpO2 (using pulse oximetry) <90% at any time 
after drug administration [9].
•	 Hypoventilation/apnea:	Poor	breathing	efforts	or	cessation	of	
respiration for more than 20 s [10].
•	 Upper	airway	obstruction	in	the	form	of	excessive	secretions	
or spasm.
•	 Hemodynamic	 changes:	 Tachycardia,	 bradycardia,	 or	
hypotension (systolic blood pressure <5th percentile of 
normal for patients’ age) [10].
•	 Hypersensitivity	to	the	sedation	agent	used.
•	 Paradoxical	agitation:	Sustained	severe	irritability	for	30	min	
or more after procedure [11].
•	 Nasal	 irritation:	 Increased	 irritability	 or	 watery	 nasal	
discharge after drug administration by intranasal route, 
which was transient [4].
The results of the sedation scores, ease of procedure scores, 
number of completed cases, and adverse effects noted in both 
groups were tabulated and statistically analyzed using SPSS 
version 11. Mean age was compared between the two groups 
using Student’s t-test. The comparison of procedures between 
two groups was done by Chi-square test. Ordinal data obtained 
with the scoring scales were analyzed using the non-parametric 
Mann–Whitney U Test at the 95% significance level, to compare 
the effectiveness of the groups. p<0.05 was considered as the 
level of statistical significance.
RESULTS
Baseline characteristics such as age, sex, and procedure 
distribution were comparable between the two groups (Table 1 
and Fig. 1). Of the 246 children enrolled in the study, 75% 
children were in the age group between 6 months and 6 years and 
57% of the total children underwent invasive procedures. The 
median interquartile range for age was 4 years.
Intranasal midazolam provided significantly better sedation 
scores (deeply sedated and unarousable) than IV midazolam for 
all procedures (p<0.001) (Table 2). The sedation scores were 
better with intranasal midazolam, especially, in the younger age 
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group of 6 months–6 years (p<0.001); while in the age group 
from 6 years to 12 years, IV midazolam achieved significantly 
better sedation scores (p<0.001) (Fig. 2).
Intranasal midazolam provided better ease of procedure 
scores compared to IV midazolam for all procedures (p=0.026). 
For invasive procedures, intranasal midazolam provided better 
ease of procedure scores compared to IV midazolam (p=0.023). 
For non-invasive procedures, although not statistically 
significant, intranasal midazolam provided better ease of 
procedure scores compared to IV midazolam. The ease of 
procedure scores for both invasive and non-invasive procedures 
were significantly better with intranasal midazolam in the age 
group between 6 months and 6 years while above 6 years to 
12 years, scores were significantly better with IV midazolam 
(p<0.001) (Table 3).
For invasive procedures, both intranasal midazolam and IV 
midazolam showed comparable rates of successful procedure 
completion. For non-invasive procedures, even though intranasal 
midazolam showed a higher successful procedure completion 
rate when compared to IV midazolam, it was not found to be 
statistically significant.
The most commonly done procedures were lumbar puncture 
and CT scan for which intranasal midazolam gave higher 
successful procedure completion compared to IV midazolam 
although	this	was	not	statistically	significant.	Nasal	irritation	was	
Table 1: Baseline characteristics of study subjects
Baseline data Intranasal 
midazolam 
n=123 (%)
Intravenous 
midazolam 
n=123 (%)
Mean age (years), SD* 3.3, 3.4 4.3, 3.5
Male 71 (57.7) 63 (51.2)
Female 52 (42.3) 60 (48.8)
Invasive procedures 73 (59.3) 69 (56.1)
Non‑invasive	procedures 50 (40.7) 54 (43.9)
Procedures
Lumbar puncture 60 (48.8) 55 (44.7)
MRI 18 (14.6) 35 (28.5)
CT 23 (18.7) 7 (5.7)
Others 22 (17.9) 26 (21.1)
*: Standard deviation. Baseline characteristics such as age, sex, and procedure 
distribution were comparable between the two groups, CT: Computed tomography, 
MRI: Magnetic resonance imaging
Table 2: Comparison of sedation scores in total
Sedation score Intranasal 
n=123 (%)
Intravenous 
n=123 (%)
p
0=Awake alert 9 (7.3) 9 (7.3) p<0.001
1=Minimally sedated 10 (8.1) 10 (8.1) p<0.001
2=Moderately sedated 24 (19.5) 66 (53.7) p<0.001
3=Deeply sedated 67 ( 54.5) 28 (22.8) p<0.001
4=Unarousable 13 (10.6) 10 (8.1) p<0.001
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Figure 1: Consort flowchart - trial profile of midazolam in procedural sedation
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a	common	side	effect	with	intranasal	midazolam	(p≤0.001).	No	
serious side effects were noted with intranasal midazolam.
DISCUSSION
This study compared the role of midazolam in pediatric procedural 
sedation when administered by two different routes, the standard 
established	IV	and	the	newer	intranasal	route.	Notably,	previous	
studies have compared different routes of administration of 
midazolam, but no study could be identified where intranasal 
midazolam was compared with IV midazolam for pediatric 
procedural sedation.
Our study showed that intranasal midazolam provided better 
sedation and ease of doing procedures for both invasive and 
non-invasive procedures compared to IV midazolam, especially 
in young children between 6 months and 6 years of age. In our 
study population of 246 children, procedural sedation was most 
commonly given for CT, lumbar puncture, and MRI. Although not 
statistically significant, for CT and lumbar puncture, intranasal 
midazolam showed higher procedure completion rates. Reduced 
efficacy for MRI may have been due to the longer duration of 
sedation required for completion of MRI. Importantly, intranasal 
midazolam showed a better safety profile compared to the IV 
route; nasal irritation being the only frequent side effect was 
self-limited. There were limitations to our study. First, we did 
not measure the time of onset of sedation, duration of sedation, 
and the recovery time. Furthermore, we could not objectively 
measure the depth of sedation achieved. The intervention could 
not be blinded as the routes of drug administration were different; 
hence, observers could differentiate between the wide variability 
of response to the different routes.
Studies have been conducted in different parts of the world 
regarding the use of intranasal midazolam for minor invasive 
procedures such as laceration repair, abscess drainage, suturing, 
venepuncture, and dental procedures as well as for non-invasive 
procedures such as CT scans and audiometry. All these studies 
showed good degrees of sedation enabling procedures to be 
completed without additional drugs, which were reflected in our 
study as well [12-14]. Regression analysis in some earlier studies 
has also shown that in younger children, the onset of sedative 
effect of intranasal midazolam is quicker. Such variability among 
different age groups may be explained by age-related variation in 
the pharmacodynamics and pharmacokinetics of midazolam due to 
both genetic polymorphisms and maturation of drug metabolizing 
enzymes. Parents as well as doctors have shown have high levels 
of satisfaction with the efficacy of intranasal midazolam [2]. Most 
of the other studies used intranasal midazolam at a higher dose of 
0.4–0.5mg/kg [13,14]. At a higher dose, the duration of action of 
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Figure 2: Comparison of sedation scores based on group and age
Table 3: Comparison of ease of procedure in different age groups for invasive and non-invasive procedures
Ease of 
procedure*
Invasive procedures Non-invasive procedures
6 months–6 years n (%) ≥6 years–12 years n (%) 6 months–6 years n (%) ≥6 year–12 years n (%)
INM# IVM$ INM# IVM$ INM# IVM$ INM# IVM$
1 2 (3.2) 6 (11.5) 3 (30) 1 (5.9) 1 (2.9) 7 (20) 5 (33.3) 0 (0)
2 1 (1.6) 16 (30.8) 5 (50) 2 (11.8) 4 (11.4) 18 (51.4) 9 (60) 1 (5.3)
3 40 (63.5) 26 (50) 2 (20) 4 (23.5) 9 (25.7) 9 (25.7) 1 (6.7) 5 (26.3)
4 20 (31.7) 4 (7.7) 0 (0) 10 (58.8) 21 (60) 1 (2.9) 0 (0) 13 (68.4)
p <0.001 <0.001 <0.001 <0.001
*Ease of procedure scores 1: Violent movements; 2: Continuous movements; 3: Controllable movements; 4: No movements, no crying. INM#: Intranasal midazolam, 
IVM$: Intravenous midazolam
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intranasal midazolam would perhaps be longer. Some previous 
studies have also considered repeating the dose of intranasal 
midazolam till the desired level of sedation is achieved [14]. Thus, 
we found that intranasal midazolam can be safely administered 
in younger children for pediatric procedural sedation. This may 
be especially useful in resource-limited peripheral centers. 
Furthermore, it provided increased patient compliance, rendering 
aggressive physical retention unnecessary.
CONCLUSION
Intranasal midazolam is an effective procedural sedative; 
especially, in young children between 6 months and 6 years of age 
with no significant adverse effects. It will be particularly useful in 
resource-limited settings.
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